---
title: "ADT's 2027 renewal: the oncology line item — ClearOnc"
description: A ~12,500-person plan carries ~$52M of cancer cost. See the 1% — worth ~$2.2M/yr — and the metrics to track it, before your August renewal.
---

A 1% improvement on ADT's plan is worth

*~$2.2M* / year

Asymmetric risk, measurable upside — exactly the kind of line analytics should own.

Total annual plan spend

~$219M

~12,500 employees × $17,496 national avg cost.

Estimated oncology spend

~$52M

23.9% of plan spend, growing with no matching outcome gain.

Single-claim exposure

$4.3M

Highest single cancer claim in 2024 — one event on a self-funded plan.

## The analytics layer for your oncology spend

A field-services workforce skews older — raising the incidence of high-cost cancers and the odds of a catastrophic claim. The problem isn't just the spend; it's that most plans can't *see* where it's leaking until the claim has landed.

**ClearOnc is Moffitt-powered navigation with the reporting to prove it.** Site-of-care and specialty-drug routing, biomarker-appropriate therapy, survivorship adherence — and the dashboard that lets you track every one:

**Avoided admissions**ER and inpatient events prevented through early navigation.

**Biomarker-appropriate %**Share of members on therapy matched to their tumor profile.

**Survivorship adherence**Care-plan completion that cuts recurrence and absenteeism cost.

## Where the 1% hides

The gaps the claims data won't surface on its own — each one is something ClearOnc closes.

11 of 20

costliest injectable drugs treat cancer — specialty-drug routing is where dollars leak.

8%

of lung-cancer patients get full NCCN biomarker testing — so plans fund therapies that can't work.

1 in 3

cancer patients ever get a survivorship care plan — driving avoidable recurrence cost.

7–9%

annual cost growth with no outcome gain — a 13-year high you can't analyze away.

## 20 minutes, before your August renewal

We'll pull ADT's actual oncology exposure and the metrics to track it.

[Book your oncology spend review →](https://meetings-na2.hubspot.com/mike-lavance?uuid=d0d822af-9b7f-4fb9-ac63-8b666b071d1c&company=ADT) [Run your full breakdown](https://clearonc.com/oncology-exposure?company=ADT&headcount=12500&industry=field&hsLang=en)